NASDAQ · EYPT
Healthcare · Biotechnology
$4.58
Up+$0.02 (+0.33%)
Updated Sep 6, 2026, 7:13 AM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
EYPT closed at $4.58 after 20 trading sessions, down 64.96% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $4.53 | $4.69 | $4.485 | $4.58 | 1.9M |
| Sep 3, 2026 | $4.74 | $4.915 | $4.455 | $4.565 | 2.63M |
| Sep 2, 2026 | $4.36 | $4.81 | $4.325 | $4.79 | 4.72M |
| Sep 1, 2026 | $4.40 | $4.61 | $4.35 | $4.58 | 3.26M |
| Aug 31, 2026 | $4.44 | $4.585 | $4.37 | $4.50 | 3.51M |
| Aug 28, 2026 | $4.59 | $4.67 | $4.36 | $4.48 | 4.39M |
| Aug 27, 2026 | $4.93 | $4.99 | $4.50 | $4.63 | 6M |
| Aug 26, 2026 | $5.025 | $5.07 | $4.93 | $4.99 | 3.26M |
| Aug 25, 2026 | $4.98 | $5.285 | $4.96 | $5.005 | 4.13M |
| Aug 24, 2026 | $5.17 | $5.35 | $4.87 | $4.87 | 4.16M |
| Aug 21, 2026 | $5.475 | $5.50 | $4.975 | $5.32 | 8.19M |
| Aug 20, 2026 | $6.18 | $6.29 | $5.295 | $5.40 | 7.41M |
| Aug 19, 2026 | $6.038 | $6.345 | $5.63 | $6.30 | 8.79M |
| Aug 18, 2026 | $4.73 | $5.52 | $4.7032 | $5.47 | 16.24M |
| Aug 17, 2026 | $4.06 | $4.90 | $3.95 | $4.87 | 52.27M |
| Aug 14, 2026 | $13.53 | $14.76 | $13.40 | $14.75 | 2.51M |
| Aug 13, 2026 | $13.59 | $13.6938 | $13.25 | $13.48 | 1.2M |
| Aug 12, 2026 | $13.05 | $13.77 | $13.02 | $13.53 | 2.26M |
| Aug 11, 2026 | $13.105 | $13.105 | $12.37 | $13.05 | 2.06M |
| Aug 10, 2026 | $14.22 | $14.32 | $13.02 | $13.07 | 1.76M |
The latest Smart Investors Daily articles mentioning EYPT.
EYPT research
Company profile and research snapshot.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 2, 2026 | TD Cowen | Hold | — |
| Aug 18, 2026 | RBC Capital | Sector Perform | — |
| Aug 18, 2026 | Chardan Capital | Neutral | — |
| Aug 18, 2026 | HC Wainwright & Co. | Neutral | — |
| Aug 18, 2026 | Citigroup | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Aug 27, 2026
Apellis and Lytenava, mentioned by EyePoint, confirm that it is possible to overcome the failure of one pivotal trial. See why I rate EYPT stock a strong buy.
SeekingAlpha · Aug 19, 2026
Eyepoint Pharmaceuticals (EYPT) plunged ~70% after its LUGANO Phase 3 trial for Duravyu in wet AMD failed the primary endpoint due to an anomalous cohort.
SeekingAlpha · Aug 19, 2026
EyePoint, Inc. is rated a Sell, citing unfavorable risk/reward and concerns about commercial relevance against standard-of-care. Read more on EYPT stock here.
Benzinga · Aug 18, 2026
EYPT releases topline results from Phase 3 LUGANO trial for wet AMD treatment. While primary endpoint was not met, secondary endpoints showed progress. Analysts adjust price targets.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning EYPT.
